NATCO Pharma rights issue offers a clear opportunity for investors looking to capitalize on the recent ₹1,279.36 crore approval.
Read MoreNATCO Pharma rights issue offers a clear opportunity for investors looking to capitalize on the recent ₹1,279.36 crore approval.
Read More
